PDCD1 and non-small cell lung carcinoma: Furthermore, immunotherapy, especially immune checkpoint inhibitors targeting programmed cell death 1 (PD-1) and its ligand PD-L1, has been integrated into neoadjuvant and adjuvant treatment plans, thereby enhancing long-term outcomes and transforming the management of early-stage NSCLC [8,9].